Prediction of potential inhibitors against SARS-CoV-2 endoribonuclease: RNA immunity sensing

Al-Rashedi, Nihad A.M.; Munahi, Murad G.; AlObaidi, Laith A.H.

doi:10.1080/07391102.2020.1863265

Cited by 13 publications

(12 citation statements)

References 41 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…dexibuprofen [ 68 ], midostaurin [ 69 ], paclitaxel [ 70 ], ponatinib [ 71 ], regorafenib [ 72 ]), or on another viral important point (e.g. nilotinib on nsp13 [ 73 ], isoprenaline on nsp9 [ 74 ], docetaxel on nsp14 [ 75 ], enzastaurin on nsp15 [ 76 ], entrectinib on nsp16 [ 77 ]). There are also drugs that can act on host and virus interactions (e.g.…”

Section: Resultsmentioning

confidence: 99%

Network analytics for drug repurposing in COVID-19

Popescu

Martin

et al. 2021

Briefings in Bioinformatics

View full text Add to dashboard Cite

To better understand the potential of drug repurposing in COVID-19, we analyzed control strategies over essential host factors for SARS-CoV-2 infection. We constructed comprehensive directed protein–protein interaction (PPI) networks integrating the top-ranked host factors, the drug target proteins and directed PPI data. We analyzed the networks to identify drug targets and combinations thereof that offer efficient control over the host factors. We validated our findings against clinical studies data and bioinformatics studies. Our method offers a new insight into the molecular details of the disease and into potentially new therapy targets for it. Our approach for drug repurposing is significant beyond COVID-19 and may be applied also to other diseases.

show abstract

Section: Resultsmentioning

confidence: 99%

Network analytics for drug repurposing in COVID-19

Popescu

Martin

et al. 2021

Briefings in Bioinformatics

View full text Add to dashboard Cite

show abstract

“…To our knowledge, this is the first demonstration of antiviral activity of capmatinib in cell-based coronavirus infection assays. While this manuscript was in preparation, other computational approaches predicted binding of capmatinib to the SARS-CoV-2 S protein, viral proteases, RNA-dependent RNA polymerase and/or viral endoribonuclease 61 – 63 . While our analysis indicates that capmatinib may act by targeting IRAK signaling, and we find a novel requirement for IRAK1/4 in supporting human coronavirus infection, the mechanism of antiviral action of capmatinib warrants further investigation in future studies.…”

Section: Discussionmentioning

confidence: 99%

Multiscale interactome analysis coupled with off-target drug predictions reveals drug repurposing candidates for human coronavirus disease

Sugiyama

Cui

Redka³

et al. 2021

Sci Rep

View full text Add to dashboard Cite

The COVID-19 pandemic has highlighted the urgent need for the identification of new antiviral drug therapies for a variety of diseases. COVID-19 is caused by infection with the human coronavirus SARS-CoV-2, while other related human coronaviruses cause diseases ranging from severe respiratory infections to the common cold. We developed a computational approach to identify new antiviral drug targets and repurpose clinically-relevant drug compounds for the treatment of a range of human coronavirus diseases. Our approach is based on graph convolutional networks (GCN) and involves multiscale host-virus interactome analysis coupled to off-target drug predictions. Cell-based experimental assessment reveals several clinically-relevant drug repurposing candidates predicted by the in silico analyses to have antiviral activity against human coronavirus infection. In particular, we identify the MET inhibitor capmatinib as having potent and broad antiviral activity against several coronaviruses in a MET-independent manner, as well as novel roles for host cell proteins such as IRAK1/4 in supporting human coronavirus infection, which can inform further drug discovery studies.

show abstract

“…To our knowledge, this is the first demonstration of antiviral activity of capmatinib in cell-based coronavirus infection assays. While this manuscript was in preparation, other computational approaches predicted binding of capmatinib to the SARS-CoV-2 S protein, viral proteases, RNAdependent RNA polymerase and/or viral endoribonuclease [54][55][56] . While our analysis indicates that capmatinib may act by targeting IRAK signaling, and we find a novel requirement for IRAK1/4 in supporting human coronavirus infection, the mechanism of antiviral action of capmatinib warrants further investigation in future studies.…”

Section: Capmatinib As An Antiviral Drug For Covid-19 and Other Human Coronavirus Diseasesmentioning

confidence: 99%

Multiscale interactome analysis coupled with off-target drug predictions reveals drug repurposing candidates for human coronavirus disease

Sugiyama

Cui

Karimzadeh

et al. 2021

Preprint

View full text Add to dashboard Cite

The COVID-19 pandemic has led to an urgent need for the identification of new antiviral drug therapies that can be rapidly deployed to treat patients with this disease. COVID-19 is caused by infection with the human coronavirus SARS-CoV-2. We developed a computational approach to identify new antiviral drug targets and repurpose clinically-relevant drug compounds for the treatment of COVID-19. Our approach is based on graph convolutional networks (GCN) and involves multiscale host-virus interactome analysis coupled to off-target drug predictions. Cell-based experimental assessment reveals several clinically-relevant repurposing drug candidates predicted by the in silico analyses to have antiviral activity against human coronavirus infection. In particular, we identify the MET inhibitor capmatinib as having potent and broad antiviral activity against several coronaviruses in a MET-independent manner, as well as novel roles for host cell proteins such as IRAK1/4 in supporting human coronavirus infection, which can inform further drug discovery studies.

show abstract

Prediction of potential inhibitors against SARS-CoV-2 endoribonuclease: RNA immunity sensing

Cited by 13 publications

References 41 publications

Network analytics for drug repurposing in COVID-19

Network analytics for drug repurposing in COVID-19

Multiscale interactome analysis coupled with off-target drug predictions reveals drug repurposing candidates for human coronavirus disease

Multiscale interactome analysis coupled with off-target drug predictions reveals drug repurposing candidates for human coronavirus disease

Contact Info

Product

Resources

About